[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100070575":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":7,"locations":15,"responsibleParty":7,"collaborators":7,"id":29,"slug":30,"hasResults":31,"nctId":32,"briefTitle":33,"officialTitle":33,"acronym":7,"eligibilityCriteria":34,"healthyVolunteers":31,"sex":35,"minAge":36,"maxAge":7,"enrollmentInfo":37,"targetDuration":7,"studyType":39,"phases":40,"briefSummary":42,"conditions":43,"keywords":45,"overallStatus":50,"whyStopped":7,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":60,"locationsCount":61},{"fullName":5,"class":6},"Novartis","INDUSTRY",null,[9],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":7},"DRUG","Tegaserod",[13],{"name":5,"affiliation":5,"role":14},"STUDY_DIRECTOR",[16],{"facility":17,"status":7,"city":18,"state":19,"zip":20,"country":21,"countryCode":22,"cosmosGeoPoint":23,"geoPoint":28,"contacts":7},"http:\u002F\u002Fwww.novartisclinicaltrials.com\u002Fetrials\u002FDiseaseID21\u002FDyspepsia-clinical-trials.go","East Hanover","New Jersey","07936","United States","US",{"type":24,"coordinates":25},"Point",[26,27],-74.36487,40.8201,{"lat":27,"lon":26},"100070575","phase-3-the-role-of-tegaserod-therapy-in-the-management-of-dyspeptic-symptoms-in-female-patients-on-proton-pump-inhibitors-for-the-treatment-of-heartburn-100070575",false,"NCT00171470","The Role of Tegaserod Therapy in the Management of Dyspeptic Symptoms in Female Patients on Proton Pump Inhibitors for the Treatment of Heartburn.","Inclusion Criteria:\n\n* Female patients 18 years or older.\n* Self-reported presence of symptoms consistent with dyspepsia (including mid-upper abdominal discomfort characterized by post prandial fullness, early satiety and bloating)\n* Stable dose PPI therapy of at least 4 weeks\n\nExclusion Criteria:\n\n* History of intestinal obstruction, symptomatic gallbladder disease, suspected sphincter of Oddi dysfunction, or of abdominal adhesions.\n* Evidence that the dyspeptic symptoms are relieved by defecation and\u002For associated with a change in frequency or stool form.\n* With a current most bothersome symptom of heartburn.\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply.","FEMALE","18 Years",{"count":38,"type":7},60,"INTERVENTIONAL",[41],"PHASE3","Study to provide initial data to assess the safety and efficacy of tegaserod use in patients with dyspepsia that are being treated with proton pump inhibitors (PPI's) for heartburn.",[44],"Dyspepsia",[46,47,48,49],"dyspepsia","hearburn","female","PPI","COMPLETED","2008-01-31",{"date":53,"type":54},"2008-02-01","ESTIMATED",{"date":56,"type":7},"2005-04",{"date":58,"type":59},"2006-08","ACTUAL",{"name":5,"class":6},1]